跳至主要内容
临床试验/ACTRN12621000310864
ACTRN12621000310864已完成未知

Microdose Antagonist Combination for Depression (MAC-D) Trial; An open label proof of concept clinical trial, using a series of subcutaneous infusions combining low dose naltrexone and flumazenil, for the treatment of major depressive disorder.

Trexapharm Pty Ltd0 个研究点目标入组 10 人开始时间: 2021年3月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Major Depressive Disorder, with any current symptoms according to DSM criteria. There will be no inclusion criteria based on symptom range or severity.
  • Treatment resistance defined as 3 (three) or more failed trials of antidepressant treatments of adequate dose and duration, which can include neurostimulation and/or completed structured psychotherapy.

排除标准

  • Patients will be excluded if they suffer hepatitis or hepatic failure, severe immunosuppression, multiple sclerosis, epilepsy or have a history of seizures, organ transplantation, are pregnant or are breastfeeding, take >5mg daily dose equivalent of Diazepam, are under 18 years of age or are unable or unwilling to provide informed consent.

研究者

发起方
Trexapharm Pty Ltd

相似试验